Selected as a Family-Friendly Company (Ministry of Gender Equality and Family), 2025

Selected as an Excellent Work–Life Balance Company in 2025 (Ministry of Employment and Labor)

Selected for the government-funded R&D program of the Osong Medical Innovation Foundation

Presented at SfN 2025 on “InsightMiner-Based Discovery of Novel AAV Capsids for Targeted Gene Therapy

Awarded the Venture Startup Promotion Merit Award (the Ministry of SMEs and Startups)

Collaborative Research and Development Agreement on AAV Gene Therapy with DongKoo Bio & Pharma

funded by a government R&D program by Ministry of SMEs and Startups

MOU Signed with the College of Pharmacy, Jeonbuk National University

MOU Signed with Ajou University Medical Center

‘BIO USA 2025’ Company Presentation

Selected for the 2025 Startup Growth Technology Leap Program (Ministry of SMEs and Startups)

Registered a patent for GXC301, a therapeutic agent for Lafora disease

ASGCT 28th Annual Meeting Abstracts, ‘AI-guided Vector Engineering for Enhanced ALS Therapy’

Published a paper on AAV delivery efficiency in IBRO Neuroscience

BIONNOVA Leaders Forum & Expo 2025 – Invited speaker

Gyeonggi -Do Governor’s Commendation for ‘Startup Founding & Job Creation’

Filed a patent of Virus Amino Acid Sequence Derivation System and Method

funded by a government R&D program by Ministry of SMEs and Startups

Presented ‘Engineering Next-Generation AAV Vectors for Enhanced ALS Therapy’ at SfN 2024 (Society for Neuroscience Meetings)

Awarded at ‘G-Star Audition Scale-Up’ Global Startup IR Competition

Filed a patent of CNS-specific peptides & AAV variants

Signed a MOU with Modalis Therapeutics Corporation, jointly developing a XOB031-mediated AAV gene therapy for Alzheimer’s disease

ODD request of GXC-301, a therapeutic agent for Lafora disease, granted by US FDA

Selected as a ‘2024 UNICORN’ and raised UDS 2M (Global Unicorn Project by Ministry of SMEs and Startups)

RPDD request of GXC-301, a therapeutic agent for Lafora disease, granted by US FDA

InsightMiner™, won a prize and a award at AI Rocket Launcher Day Season4, 2024 AI EXPO

A ‘co-developing’ Alzheimer’s disease therapeutic program with Hanyang Univ., funded by a governmental global R&D program from KHIDI

MOU signed with AJOU MBD T2B Center

Change of corporate name to GENIXCURE Inc.

Filed 4 patents of AI-based cell-specific peptides & AAVs (featuring 60 vectors)

Made a presentation of GXC-301(Lafora disease) preclinical data at 2023 Lafora Disease Science Symposium in Bologna, Italy

Filed a patent application for GXC301, a therapeutic agent for Lafora disease

Made a presentation of an AAV program at ISCT 2023 in Paris (Collaborative research with Samsung Seoul Hospital)

Signed MOUs with Kyungdong Pharmaceutical Co., Ltd. for GMP CDMO and L/O

Signed Research and Development Agreement with ToolGen

Inno-Biz Certification (Minister of Small and Medium Venture Business)

Participation in R&D projects to foster research-oriented hospitals (supervisor: Samsung Seoul Hospital)

Series A fundraising

TF launched for InsightMiner™ 1.0

Signed a MOU with MedySapiens

funded by a government R&D program by KHIDI

GXC301 funded by a government R&D program by Ministry of SMEs and Startups

Awarded ‘Appreciation of Technology Commercialization & Entrepreneurship’ from Ministry of Health and Welfare

funded 1M by a government R&D program by Ministry of Health and Welfare

Certification of venture companies

Certification of corporate research institutes

Founded